The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages

  Maymó Masip, Elsa ^a,b   Fernández Veledo, Sonia ^a,b   España, Antonio Garcia ^b   Vázquez Carballo, Ana ^a,c   Tinahones, Francisco Jóse ^d   García Fuentes, Eduardo ^d,e,f   Garrifo Sanchez, Lourdes ^a,b   Del Mar Rodriguez, Maria ^d,g   Vendrell, Joan ^a,b   Chacón, Matilde R ^a,b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f Hospitales Universitarios Regional y Virgen de la Victoria HURyVV Instituto de Investigaciones Biomédicas de Málaga IBIMA   (Spain)

^g GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FN14 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TWEAK PROTEIN; UNCLASSIFIED DRUG;

ADIPOCYTE; ADULT; AGED; ARTICLE; BARIATRIC SURGERY; BIOPSY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; MALE; MORBID OBESITY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMAL VASCULAR FRACTION; SUBCUTANEOUS FAT; UPREGULATION;

ADIPOCYTES; ADULT; BARIATRIC SURGERY; BODY MASS INDEX; CYTOKINES; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; OBESITY; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84881511197     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4177     Document Type: Article

References (37)

1. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7: 411-425.
2. ChicheporticheY, Fossati-Jimack L, Moll S, Ibnou-ZeKri N, Izui S. Downregulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun. 2000; 279:162.e5.
3. Blanco-Colio LM, Martín-Ventura JL, Muñoz-Garciía B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:916-922.
4. Chacón MR, Richart C, Gómez JM, et al. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine. 2006;33:129-137.
5. Vendrell J, Maymó-Masip E, Tinahones F, et al. Tumornecrosis-like weak inducer of apoptosis as a pro-inflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia. J Clin Endocrinol Metab. 2010;95: 2983-2992.
6. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAKcan function as a juxtacrine signaling molecule and activate the NF-αB pathway. J Biol Chem. 2010;285:17432-17441.
7. Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008;199:440-444.
8. Carrero JJ, Ortiz A, Qureshi AR, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:110-118.
9. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:367-377.
10. Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemo-attractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005;54:2277-2286.
11. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett. 2007;112:61-67 (review).
12. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461 (review).
13. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35 (review).
14. Bourlier V, Zakaroff-Girard A, Miranville A, et al. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation. 2008;117:806-815.
15. Spencer M, Unal R, Zhu B, et al. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab. 2011;96:E1990-E1998.
16. Spencer M, Yao-Borengasser A, Unal R, et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab. 2010;299:E1016-E1027.
17. Fuentes L, Wouters K, Hannou SA, et al. Down regulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotype. Diabetologia. 2011;54:3150-3156.
18. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm. 2010;2010:5139.
19. Wicovsky A, Salzmann S, Roos C, et al. TNF-like weak inducer of apoptosis inhibits pro-inflammatory TNF receptor-1 signaling. Cell Death Differ. 2009;16:1445-1459.
20. Yamana J, Morand EF, Manabu T, et al. Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes. Cell Immunol. 2012;272:293-298.
21. Echeverry R, Wu F, Haile WB, Wu J, Yepes M. The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system. J Neuroinflammation. 2012;9:45.
22. Tiller G, Fischer-Posovszky P, Laumen H, et al. Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. Endocrinology. 2009;12:5373-5383.
23. Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123: 931-944.
24. Lepur A, Carlsson MC, Novak R, Dumić J, Nilsson UJ, Leffler H. Galectin-3 endocytosis by carbohydrate independent and dependent pathways in different macrophage like cell types. Biochim Biophys Acta. 2012;1820:804-818.
25. Altman DG. Practical Statistics for Medical Research. New York: Chapman and Hall; 1991.
26. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415.
27. Cawthorn WP, Sethi JK. TNF-α and adipocyte biology. FEBS Lett. 2008;582:117-131.
28. Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. A case-control study. PLoS One. 2012;7: e43919.
29. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N. Decreased solubleTWEAKlevels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail. 2009; 11:1050-1056.
30. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793-802.
31. Schneider P, Holler N, Bodmer JL, et al. Conversion of membranebound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205-1213.
32. Müller N, Wyzgol A, Münkel S, Pfizenmaier K, Wajant H. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 2008;275:2296-2304.
33. Roos C, Wicovsky A, Müller N, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-αB pathway. J Immunol. 2010;185: 1593-1605.
34. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-αB transcription factor. Mol Cell Biol. 1990;10:2327-2334.
35. Maeda N, Takahashi M, Funahashi T, et al. PPAR ligands increaseexpression and plasma concentrations of adiponectin, anadiposederived protein. Diabetes. 2001;50:2094-2099.
36. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002;72: 847-855.
37. Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, Wajant H. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem. 2011;287:484-495.